There's mounting research to suggest that protecting people who are immuno-compromised from getting COVID is important not just for their sake – it could be critical in the effort to end the ...

Ellipses has agreed to in-license global rights to ‘GENA-104’, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, a recently discovered checkpoint protein that is highly ...